Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Placebo Effect Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Acute Effects of Onnit Alpha Brain on Cognition and Mood States

NCT07495592
View directory record Official record
Conditions
Cognitive, Mood and Cognitive Performance, Sleep Deprivation, Executive Function (Cognition), Fatigue
Interventions
Alpha Brain proprietary cognitive dietary supplement, Alpha Brain 2.0 proprietary cognitive dietary supplement, Controlled Placebo
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
20 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 15, 2026, 2:43 PM EDT
Completed No phase listed Observational

Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density

NCT00418236
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 63 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
San Diego, California • Upland, California • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.

NCT04155047
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Glyocopyrrolate Inhalation Solution administered by Magnair, Placebo administered by Magnair
Combination Product · Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Sep 15, 2026, 2:43 PM EDT
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

NCT03152552
View directory record Official record
Conditions
Diabetes Mellitus and Heart Failure
Interventions
LIK066, Placebo, Empagliflozin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 15, 2026, 2:43 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Spectroscopic Imaging at 4T: A Drug Challenge Study

NCT01577706
View directory record Official record
Conditions
AOD Effects and Consequences
Interventions
Alprazolam, Dextroamphetamine, Placebo
Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 15, 2026, 2:43 PM EDT
Recruiting Phase 1 Interventional

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

NCT06372821
View directory record Official record
Conditions
Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)
Interventions
NIO752, Placebo
Drug · Other
Lead sponsor
University College, London
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

NCT00699504
View directory record Official record
Conditions
Healthy
Interventions
cangrelor, moxifloxacin, placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG

NCT00402506
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
Interventions
(MC-1) Pyridoxal 5'-phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2007 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Results available

Metformin Postpartum for GDM RCT for Reduced Weight Retention

NCT01280409
View directory record Official record
Conditions
Diabetes, Gestational
Interventions
Metformin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Mulberry Leaf on Type 2 Diabetes

NCT00795704
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mulberry Leaf Extract, Placebo
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure

NCT00052026
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
carvedilol, placebo
Drug
Lead sponsor
Shaddy, Robert, M.D.
Individual
Eligibility
1 Day to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2008 · Synced Sep 15, 2026, 2:43 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

NCT05949008
View directory record Official record
Conditions
NIDDM, Obesity
Interventions
Metformin Extended Release (ER) Oral Tablet, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

NCT01789476
View directory record Official record
Conditions
Acute Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Capsimax Effect on Metabolic Rate, Satiety and Food Intake

NCT03489226
View directory record Official record
Conditions
Energy Metabolism, Eating, Hunger
Interventions
Capsimax, Placebo, Meal
Dietary Supplement · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence

NCT03538808
View directory record Official record
Conditions
Medication Adherence
Interventions
Varenicline, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00268216
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol 50mcg/ Fluticasone Propionate 500mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
6,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
190
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 152 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 15, 2026, 2:43 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized, Double-Blind Study to Assess the Effect of a Postbiotic on Oxidative Stress and Exercise Performance

NCT06795425
View directory record Official record
Conditions
Oxidative Stress, Healthy, Exercise-induced Muscle Damage, Exercise-induced Muscle Soreness, Immune Function, Gut Health, Microbiome Analysis, Exercise Performance, Exercise Metabolism
Interventions
Postbiotic Active Lifestyle Blend, Placebo
Dietary Supplement · Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

NCT00404014
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
AL-208, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
50 Years to 79 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Laguna Hills, California • Sacramento, California • Jacksonville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

NCT00274508
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 15, 2026, 2:43 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

NCT05972278
View directory record Official record
Conditions
Lipid Metabolism
Interventions
Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT01266525
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
SAR110894, placebo (for SAR110894), Donepezil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 15, 2026, 2:43 PM EDT
Terminated Phase 2 Interventional Results available

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

NCT01437878
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Interventions
Iloprost, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
40 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
9
States / cities
Torrance, California • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

NCT01224106
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 15, 2026, 2:43 PM EDT